d[Cha4]-AVP

发表于由

d[Cha4]-AVP; 纯度: 99.27%

d[Cha4]-AVP 是一种有效的选择性加压素 (AVP) V1b 受体激动剂，对人 V1b 受体的 Ki 为 1.2 nM。d[Cha4]-AVP 对 V1b 受体的选择性高于对人类 V1a 受体、V2 受体和催产素受体。

d[Cha4]-AVPamp;;

d[Cha4]-AVP Chemical Structure

CAS No. : 500170-27-4

规格 价格 是否有货 数量
1 mg ￥1200 In-stock
5 mg ￥3500 In-stock
10 mg ￥5600 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

d[Cha4]-AVP is a potent and selective vasopressin (AVP) V1b receptor agonist with a Ki of 1.2 nM for human V1b receptor. d[Cha4]-AVP shows more selective for V1b receptor than human V1a receptor, V2 receptor, and oxytocin receptors[1][2].

IC50 Target

Ki: 1.2 nM (vasopressin V1B receptor), 151 nM (vasopressin V1A receptor), 240 nM (Oxytocin receptor), 750 nM (vasopressin V2 receptor)[1]
体外研究
(In Vitro)

d[Cha4]-AVP binds to hV1b receptors and human oxytocin receptors with pKi values of 9.68 and 7.68, respectively[2].
d[Cha4]-AVP stimulates [Ca2+]i increase in hV1b-CHO cells with a pEC50 value of 10.05. d[Cha4]-AVP shows pEC50 values of 6.53 and 5.92 at hV1a and hV2 receptors, respectively, and behaved as a weak antagonist at hOT receptors (pKB=6.31)[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

1094.31

Formula

C50H71N13O11S2
CAS 号

500170-27-4
Sequence

{Mpa}-Tyr-Phe-{Cha}-Asn-Cys-Pro-Arg-Gly-NH2 (Disulfide bridge:Mpa1-Cys6)
Sequence Shortening

{Mpa}YF{Cha}NCPRG-NH2 (Disulfide bridge:Mpa1-Cys6)
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -80deg;C 2 years
-20deg;C 1 year
In solvent -80deg;C 6 months
-20deg;C 1 month
参考文献

  • [1]. Ling Ling Cheng, et al. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.

    [2]. Cristiana Griffante, et al. Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist. Br J Pharmacol. 2005 Nov;146(5):744-51.